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Abstract
Background: T-cell exhaustion seems to play a critical role in CD8+ T-cell dysfunction during chronic viral infections.
However, up to now little is known about the mechanisms underlying CD4+ T-cell dysfunction during chronic hepatitis B
virus (CHB) infection and the role of inhibitory molecules such as programmed death 1 (PD-1) for CD4+ T-cell failure.
Methods: The expression of multiple inhibitory molecules such as PD-1, CTLA-4, TIM-3, CD244, KLRG1 and markers defining
the grade of T-cell differentiation as CCR7, CD45RA, CD57 and CD127 were analyzed on virus-specific CD4+ T-cells from
peripheral blood using a newly established DRB1*01-restricted MHC class II Tetramer. Effects of in vitro PD-L1/2 blockade
were defined by investigating changes in CD4+ T-cell proliferation and cytokine production.
Results: CD4+ T-cell responses during chronic HBV infection was characterized by reduced Tetramer+CD4+ T-cell
frequencies, effector memory phenotype, sustained PD-1 but low levels of CTLA-4, TIM-3, KLRG1 and CD244 expression. PD-
1 blockade revealed individualized patterns of in vitro responsiveness with partly increased IFN-c, IL-2 and TNF-a secretion
as well as enhanced CD4+ T-cell expansion almost in treated patients with viral control.
Conclusion: HBV-specific CD4+ T-cells are reliably detectable during different courses of HBV infection by MHC class II
Tetramer technology. CD4+ T-cell dysfunction during chronic HBV is basically linked to strong PD-1 upregulation but absent
coregulation of multiple inhibitory receptors. PD-L1/2 neutralization partly leads to enhanced CD4+ T-cell functionality with
heterogeneous patterns of CD4+ T-cell rejunivation.
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Introduction
CD4+ T-cells are known to be critical components of virus-
induced immune responses in terms of development, maintenance
and control of T-cell and B-cell immunity. Detailed properties of
CD4+ T-cell immunity during chronic viral infections remain to be
defined in contrast to CD8+ T-cell responses. So far, virus-specific
CD8+ T-cells during persisting viral diseases as human immuno-
deficiency virus (HIV), chronic hepatitis C virus (HCV) and
chronic hepatitis B virus (CHB) infection become stepwise less
functional and exhausted, a state characterized by hierarchical
disruption of CD8+ T-cells to proliferate and to produce antiviral
cytokines while memory T-cells perform vigorous effector func-
tions [1]. Sustained coexpression of multiple inhibitory molecules
such as programmed death-1 (PD-1), cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4), T-cell immunoglobulin domain
and mucin domain 3 (TIM-3), CD244 (2B4) and killer cell lectin-
like receptor G1 (KLRG1) were determined as common features
strongly associated with CD8+ T-cell exhaustion. [2–7]. Function-
al data even indicated, that neutralization of these inhibitory
pathways would be able to revive dysfunctional virus-specific
CD8+ T-cells characterized by improvement of T-cell prolifera-
tion, cytotoxicity and cytokine production [3,4,7–9]. Indeed, while
the role of inhibitory molecules in terms of CD8+ T-cell
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dysfunction is rather well characterized, a significant lack of data
did exist with respect to the CD4+ T-cell compartment, although
CD4+ T-cells are critical for successful viral control [10]. Recent
data in chronic HIV and HCV infection revealed that high PD-1
expression seems to be associated with CD4+ T-cell dysfunction,
with functional CD4+ T-cell rejuvenation following PD-L1/2
blockade [8,11,12]. Next to PD-1, sustained CTLA-4 expression
in HIV infection demonstrated strong association with disease
aggravation [7]. CD4+ T-cell dysfunction during HIV infection
seems to be controlled by complex patterns of multiple
coexpressed inhibitory receptors as previously described for
CD8+ T-cells [2,5,9,12]. However, the detailed role of PD-1,
CTLA-4 and other inhibitory receptors as TIM-3, CD244 and
KLRG1 on the development and maintenance of HBV-specific
CD4+ T-cell dysfunction has yet to be elucidated. In this study, we
therefore focused for the first time on the characterization of: (i)
the memory and inhibitory phenotype of virus-specific CD4+ T-
cells during chronic HBV infection by using a novel established
DRB1*01-restricted MHC class II Tetramer and (ii) the
functional impact of negative regulatory molecules as PD-1
measured by changes in CD4+ T-cell proliferation as well as




Peripheral blood was obtained from study subjects after
institutional review board approval from the Ethic Committee of
LMU Munich. All patients gave written informed consent. The
protocol and the procedures of the study were conducted in
conformity with ethical guidelines of the Declaration of Helsinki.
Overall, 66 patients with chronic HBV infection (CHB), 41
patients with acute HBV infection (AHB), 5 HBV resolvers (RHB)
and 7 healthy individuals were included (Table 1). Participant’s
age ranges from 18 to 65 years. Number of cases used for
immunological T-cell assays are listed in detail in Table 2.
Performance of one or more T-cell assays in each study subject
was executed according to individual cell numbers. Patients with
chronic infection have been seropositive for HBsAg for more than
6 months, anti-HBc and seronegative for HBs antibodies.
Successful antiviral treatment with nucleotid/nucleosid analogs
was defined as HBV DNA below 2.000 IU/ml. Patients with
HCV, HDV and HIV co-infection were excluded. Acute HBV
infection was diagnosed by the following criteria: acute onset of
hepatitis in previously healthy individuals, along with recent onset
of jaundice, exclusion of metabolic or toxic causes, ALT at least
10-fold upper the limit of normal, HBsAg and anti-HBc IgM
positive. HBV resolvers are seronegative for HBsAg and seropos-
itive for HBs antibodies.
Synthetic peptides
HLA-DRB1*01-restricted HBV core 61–80 (CWGELM-
TLATWVGVNLEDPA) and Influenza hemagglutinin
(PKYVKQNTLKLAT) (purity: .90%) were used (EMC Micro-
collections).
Proliferation assay
Thymidine-based proliferation assay was performed as de-
scribed previously [13].
Flow cytometric analysis
The following reagents were used: PD-1FITC, CTLA-4APC,
CD4FITC/APC-H7/V500, CD14PerCP, CD19PerCP, CD3PerCP, Via
Probe, Monensin, functional grade anti-CTLA-4 (BD Biosciences);
CD244FITC, PD-1APC, CD127APC-Cy7, IL-2FITC, IFN-cPE, TNF-
aPE-Cy7, anti-PD-L1/2 and anti-IgG1 isotype control (eBioscience);
TIM-3APC (R&D Systems); CCR7FITC, CD57PacificBlue,
CD45RAPacificBlue, functional grade anti-TIM-3 (Biolegend).
Micro-Beadsanti-PE (Miltenyi). KLRG1AlexaFluor488 (clone:
13F12F2) was generated as described [14].
MHC class II Tetramer staining
HLA-DRB1*01 MHC class II Tetramers (Beckman Coulter)
were used as listed: HBV core 60-75PE (LCWGELM-
TLATWVGVN), Influenza hemagglutininPE (PKYVKQNTLK-
LAT) and EBV EBNA1PE (TSLYNLRRGTALA). Staining and
calculation of Tetramer+ T-cells including enrichment step and
CTLA-4 staining were performed as described [11] [15]. Briefly,
lymphocytes were incubated for surface markers after staining for
Tetramers. After wash step, cells were incubated with Micro
Beads. 90% of cells were applied to MS Columns (Miltenyi). The
other 10% were reserved for FACS (pre-enrichment sample). PE-
positive cells were eluted from the column (post-enrichment
sample) and analyzed by FACS. Tetramer frequencies were
determined by dividing the number of Tetramer+CD4+ T-cells
after enrichment by the total number of input CD4+ T-cells.
In vitro expansion assay
In vitro expansion was performed with 26106 PBMC from
chronically infected subjects. After pre-incubation with anti-PD-
L1/2 (1 mg/2 mg/ml), anti-CTLA-4 (50 mg/ml) and anti-TIM-3
(10 mg/ml) for 30 min. at 37uC, cells were stimulated with HBV or
Flu peptide (10 mg/ml). At day 7, 20 IU/ml recombinant human
IL-2 (rhIL-2) was added. Based on CD4+ T-cell clone stimulation
experiments Tetramer staining was performed at day 21 revealing
highest expansion rate of virus-specific CD4+ T-cells.
Intracellular Th-1 cytokine release (ICS)
After 21 days of in vitro expansion of 36106 PBMC with HBV
core or Flu peptide in the presence or absence of anti-PD-L1/2
and 20 IU/ml rhIL-2, cells were restimulated with antigen (10 mg/
ml) in the presence of autologous irradiated (4000 rads) PBMCs
(16105/well) and Monensin (2 mM). After 6 hours of incubation,
cells were stained with surface markers, fixed, permeabilized and
stained with anti-IFN-c, anti-IL-2 and anti-TNF-a. Cells were
gated on CD3+CD4+ T-cells.
Statistical Analysis
Data were shown as mean values with SEM (standard error of
the mean). GraphPad Prism 6 was used for Mann-Whitney U test,
Wilcoxon signed rank and Chi2-test. P values of less than 0.05
were considered significant. Significance of cytokine increase has
been determined by calculating the difference between antigenic
stimulation and PD-L1/2 blockade. Patients only exceeding pre-
determined values (IFN-c .0.38; IL-2 .0.07; TNF-a .0.2) were
classified as cytokine responders upon PD-L1/2 blockade.
Unspecific in vitro reaction was excluded by using matched
isotype controls in T-cell expansion and ICS assays.
Results
Validation of DRB1*01-restricted MHC class II Tetramer
For phenotyping of HBV-specific CD4+ T-cells a DRB1*01-
restricted MHC class II Tetramer was designed based on a
previously characterized immunodominant epitope within the
HBV core antigen region on amino acid position 61–80 [16]. We
were able to demonstrate that epitope 61–80 was strongly
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recognized by CD4+ T-cells from DRB1*01-positive patients
(Fig.S1A and B). CD4+ T-cell clone characterization demonstrated
strong and specific Tetramer staining with a lower limit of
detection of 0.001% of total CD4+ T-cells in titration experiments
(Fig.S1C and D).
Virus-specific CD4+ T-cell frequencies
First, we characterized virus-specific CD4+ T-cell frequencies
during different courses of HBV infection. Study subjects with
acute HBV displayed the highest frequencies (0.056%) as
compared to chronic infection including untreated and treated
patients (0.006%) (Fig.1A). We were able to detect Epstein-Barr-
virus-specific and Influenza-specific CD4+ T-cells in CHB (EBV:
0.007%; Flu: 0.005%) and AHB (EBV: 0.0026%; Flu: 0.0016%)
(Fig.1A). CD4+ T-cell frequencies in both viral entities as tested in
acute and chronic HBV did not differ from frequencies in
chronically infected HBV patients, but were declined compared to
acute HBV infection (Fig.1A). Unspecific background of the HBV
core Tetramer was analyzed by staining DRB1*01 positive healthy
subjects (0.00%). Represantative stainings are shown in Figure 1B.
In order to rule out variations of Tetramer frequencies with
respect to viral load, we performed longitudinal measurements in 5
chronically infected patients before and during treatment with
nucleosid/nucleotide analogs. Analysis revealed a slight decrease
of CD4+ T-cell frequencies from the pre-treatment phase (0.015%)
up to a 2-year follow-up with viral control upon therapy initiation
(year 1: 0.0033%; year 2: 0.0015%) (data not shown). No
significant differences in Tetramer frequencies exists regarding
antiviral therapy and viral load, HBeAg status as well as GPT
levels (data not shown).
Virus-specific CD4+ T-cell differentiation
Successful immune control depends on balanced T-cell
differentiation, why we analyzed in a first set of experiments the
state of CD4+ T-cell differentiation during acute-resolving and
chronic HBV infection according to the differentiation model of
CD8+ T-cells [17]. Tetramer+CD4+ T-cells basically displayed the
effector memory phenotype (Tem, CCR7negCD45RAneg) in acute
(68.1%) and chronic HBV (64.5%), followed by central memory
CD4+ T-cells (Tcm, CCR7posCD45RAneg) (Fig.1C). Terminally
differentiated (CCR7negCD45RApos) and naive (CCR7posC-
D45RApos) CD4+ T-cells were almost absent (Fig.1C). Tem
CD4+ T-cells during chronic HBV were more frequent than Tcm,
Teff and Tnaive CD4+ T-cells. Overall, patterns of HBV-specific
CD4+ T-cell differentiation revealed no differences in acute and
chronic HBV infection as well as in chronic untreated and treated
HBV patients (data not shown). Interestingly, total CD4+ T-cells in
chronic and acute HBV infection displayed shortened but
assimilable data for Tem (36.8% vs. 29.7%), Tcm (28.9% vs.
31.2%) and naive CD4+ T-cells (30.7% vs. 35.7%), with low
frequencies for terminally differentiated CD4+ T-cells (3.3% vs.
3.2%), if compared to HBV-specific Tetramer+CD4+ T-cells.
Representative stainings are shown in Figure 1D. As we know,
that CD57 represents senescent and terminally differentiated
lymphocytes with disrupted T-cell proliferation, we examined
CD57 expression in HBV, EBV and Flu infection. CD57 is rarely
expressed in acute (20.4%) and chronic HBV (5.9%) as well as on
EBV- (17.4%) and Flu-specific CD4+ T-cells (0.8%) (Fig.S2A and
B).
Expression patterns of multiple inhibitory molecules in
chronic HBV
Similar profiles of CD4+ T-cell differentiation in acute-resolving
and chronic HBV infection suggested preserved ability of memory
Table 1. Baseline Characteristics*.
Hepatitis B virus infection CHBuntreated CHBtreated** AHB
number (n) n = 42 n = 23 n = 8
sex (female/male) 20/22 7/16 2/6
age (years) 39 (19–65) 48 (18–65) 37 (24–63)
HBV DNA (IU/ml) 600 0 n.d.***
ALT (U/L) 36 (12–860) 33 (17–590) 400 (21–2100)
HBeAg (negative/positive/n.d.**) 28/6/8 10/5/8 0/2/6




Table 2. Immunological assays and number of patient cases.
Material and Methods CHB (n = 66*) AHB (n = 41*)/RHB (n = 5) healthy (n = 7*)
HLA-DRB1*01 positive n = 66 n = 8/5 n = 7
Thymidine-based proliferation assay n = 0 n = 38/5 n = 0
MHC class II Tetramer staining (HBV/EBV/Flu) n = 30/15/21 n = 8/0/0/5/0/0 n = 7/0/0
CD4+ T-cell expansion assay n = 23 n = 0/0 n = 0
ICS n = 13 n = 0/0 n = 0
*overall number of patients included into study.
doi:10.1371/journal.pone.0105703.t002
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CD4+ T-cell generation even during persisting viral infection. We
consecutively asked for further reasons for CD4+ T-cell dysfunc-
tion. Since we know that T-cell exhaustion is a common feature
for dysfunctional CD8+ T-cells, we characterized multiple
inhibitory molecules on virus-specific CD4+ T-cells of overall 30
chronically infected HBV patients. CD4+ T-cells most frequently
expressed PD-1 (77.9%) in contrast to CTLA-4 (19.6%), TIM-3
(12.9%), KLRG1 (6.4%) and CD244 (5.5%) (Fig.2A). Chronic
HBV infection was associated with strong PD-1 expression when
compared to Flu-specific (20.9%) and EBV-specific CD4+ T-cells
(38.6%) (Fig.2B). Patients with acute HBV displayed high PD-1
expression (70.7%), comparable to chronic HBV infection
(Fig.2B). However, in case of viral clearance, PD-1 expression
declined significantly in RHB (36.9%) (Fig.2B). To define the
influence of T-cell differentiation on the inhibitory phenotype, we
determined PD-1 on Tcm, Tem and naive CD4+ T-cells. PD-1
expression was quite similar expressed on Tcm (77%) and Tem
(72.1%), but strongly decline on naive CD4+ T-cells (1.5%) (data
not shown). Notably, virus-specific PD-1 expression in CHB was
not influenced by antiviral therapy and viral load as dissected in
Figure S2C. Stainings of PD-1 expression are shown in Figure 2C.
CD127 defines virus-specific PD-1 expression
Next, we asked for the linkage of CD127 and PD-1 expression
as shown for CD8+ T-cells [2,18]. CD127 was downregulated
during chronic HBV (54.8%) as compared to Flu infection (n = 9)
(89.8%) (Fig.2D). Representative stainings are shown in Figure 2E.
Depending on CD127 expression above or below 60% (pre-
defined cut-off in healthy subjects), we defined CD127high and
CD127low expressing CD4+ T-cells. Tetramer+CD127highCD4+
T-cells displayed less PD-1 expression (55% vs. 84.3%) (Fig.2F)
and decreased viral load (10 vs. 1.76106 IU/ml) (Fig.2G) as
compared to CD127lowCD4+ T-cells (p = 0.009 and p = 0.02,
respectively).
PD-L1/2 blockade reactivates CD4+ T-cell proliferation
Further, we characterized the reactivation of CD4+ T-cell
proliferation during chronic HBV following PD-L1/2 neutraliza-
tion in the presence of HBV core antigen as PD-1 represents the
strongest linkage to chronic HBV. We were able to classify: (1)
PD-L1/2 responders (R) with enhancement of Tetramer+CD4+ T-
cell frequencies from 1.3% to 2.2% (p = 0.004) (Fig.3A) and (2)
PD-L1/2 non-responders (NR) with decreased frequencies from
0.9% to 0.5% (p = 0.0001) (Fig.3B). Both groups revealed strong
Figure 1. Virus-specific CD4+ T-cell frequencies and memory phenotype. (A) Tertamer+CD4+ T-cell frequencies in acutely (n = 8) and
chronically (n = 30) infected HBV patients versus healthy controls (n = 7), influenza- and EBV-specific CD4+ T-cells as tested in CHB (Flu: n = 21; EBV:
n = 15) and AHB (Flu/EBV: n = 6). (B) Representative contour plots are gated on CD142, CD192, Via Probe2 CD4+ T-cells following enrichment step. (C)
Expression of CD45RA and CCR7 on Tetramer+CD4+ T-cells during chronic (black bars) (n = 8) and acute HBV (striped bars) (n = 6). (D) Contour plots of
effector memory (Tem; CCR7
negCD45RAneg), central memory (Tcm; CCR7
posCD45RAneg), effector (Teff; CCR7
negCD45RApos) and naive (Tnaive;
CCR7posCD45RApos) CD4+ T-cell subsets during chronic and acute HBV.
doi:10.1371/journal.pone.0105703.g001
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CD4+ T-cell expansion from ex vivo frequencies of 0.002% (R)
and 0.007% (NR) to 1.3% (R) and 0.9% (NR) upon antigenic
restimulation. Notably, treated patients with long-term viral
control commonly responded to PD-1 blockade, while untreated
high viremic (5.26106 IU/ml) subjects failed to revive T-cell
proliferation (p = 0.02 and p = 0.01, respectively) (Fig.3C and D).
Interestingly, responsiveness of PD-1 neutralization was not
associated with viral load within the group of chronically untreated
HBV patients (data not shown). PD-L1/2 responders are
characterized by slightly reduced PD-1 expression (63.3%) in
contrast to non-responders (89.3%) (Fig.3E). Indeed, CD4+ T-cell
responsiveness seems to depend on PD-1 expression (Fig.3F). We
found, that PD-1 expression higher than 90% (PD-1high) versus
PD-1 less than 90% (PD-1low) limited the ability of CD4+ T-cells to
proliferate in response to antigen (p = 0.01) and PD-L1/2 blockade
(p = 0.01). Of note, PD-L1/2 inhibition failed to rescue Flu-
specific CD4+ T-cell proliferation (Fig.S3). Next, we asked for the
effect of CTLA-4 and TIM-3 inhibition on CD4+ T-cell
expansion. Neither CTLA-4 (p = 0.21) nor TIM-3 (p = 0.12)
blockade were able to reactivate Tetramer+CD4+ T-cell frequen-
cies in chronically infected HBV patients when compared to
antigenic stimulation alone (Fig.S3).
PD-L1/2 blockade improves the ability of CD4+ T-cells to
produce Th-1 cytokines
Next to T-cell proliferation, we addressed the question if PD-1
inhibition would be able to reactivate IFN-c, IL-2 and TNF-a
production. PD-L1/2 blockade reactivates at least one of the
investigated cytokines in 4 of 13 chronic HBV patients, classified
as PD-L1/2 responders with enhanced cumulative CD4+ T-cell-
related cytokine production from 0.67% to 2.1% (p = 0.004).
Cytokine rejunivation upon PD-L1/2 inhibition was almost
characterized by increased CD4+IFN-c+ (1.0% to 2.7%) and
CD4+TNF-a+ T-cells (0.63% to 2.47%) with only slight enhance-
ment of CD4+IL-2+ T-cells (0.046% to 0.32%) (Fig.4A). In
contrast, 9 of 13 patients were classified as PD-L1/2 non-
responders with an overall decrease of cytokine production from
0.47% to 0.31% (p = 0.002). Declined patterns of CD4+IFN-c+
(0.38% to 0.19%), CD4+IL-2+ (0.14% to 0.096%) and CD4+TNF-
a+ (0.93% to 0.65%) are dissected in Figure 4B.
Discussion
Upregulation of inhibitory molecules during chronic viral
infections display a critical mechanism thought to be crucial for
Figure 2. Inhibitory phenotype of HBV-specific CD4+ T-cells. (A) PD-1 (n = 29), CTLA-4 (n = 8), TIM-3 (n = 14), KLRG1 (n = 12) and CD244 (n = 8)
expression is displayed on Tetramer+CD4+ T-cells during chronic HBV. (B) PD-1 expression in chronic (black points) (n = 29) and acute HBV (black
squares) (n = 7), resolved HBV (white squares) (n = 5), EBV (grey points) (n = 15) and Flu (white points) (n = 21) infection. (C) Contour plots illustrate
patterns of PD-1 expression during HBV, EBV and Flu infection. (D) CD127 expression on HBV-specific (black points) (n = 11) and Flu-specific CD4+ T-
cells (white points) (n = 9). (E) Contour plots display CD127 expression on CD142, CD192, Via Probe2, Tetramer+ T-cells. (F) CD127 defines PD-1
expression as examined in HBV (black bars) and Flu infection (white bar). (G) Influence of viral load on CD127 expression.
doi:10.1371/journal.pone.0105703.g002
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CD8+ T-cell failure [2–5,7,19]. Sustained PD-1 and CTLA-4
expression was highlighted as a hallmark for CD8+ T-cell
exhaustion with rejunivation of T-cell function following in vitro
blockade of both molecules [20,21]. CD8+ T-cell exhaustion is
additionally associated with coexpression of PD-1, CTLA-4, TIM-
3 and CD244 with improvement of T-cell responses following
simultaneous neutralization [2,7,9,19,22]. In contrast, CD4+ T-
cell exhaustion remains less well understood, although CD4+ T-
cells are critical for the control and elimination of viral diseases
[10]. A major limitation for virus-specific CD4+ T-cell character-
ization is their relative paucity once chronic infection is established
[23-25]. To illuminate features of CD4+ T-cell dysfunction during
chronic HBV infection, we analyzed (i) the memory and
inhibitory phenotype of Tetramer+CD4+ T-cells as well as (ii)
the capacity of PD-L1/2 neutralization to reactivate CD4+ T-cell
function as PD-1 expression is suggested to be crucial during
chronic HBV. Although MHC class II Tetramers are rarely used
for analysis of antigen-specific CD4+ T-cells, we established one
newly DRB1*01-restricted Tetramer to track antigen-specific
CD4+ T-cells during HBV infection [10,11,15,25]. Our results
indicate, that Tetramer+CD4+ T-cells are reliably detectable even
during the chronic phase of HBV assigning one basic principle for
CD4+ T-cell phenotyping. Of note, it must be pointed out that
results are in reference to CD4+ T-cells only specific to HBV core
epitope 61–80. As we know, that immune control depends on
balanced distribution of effector and memory T-cells, we first
determined the state of virus-specific CD4+ T-cell differentiation in
acute-resolving and chronic HBV infection. CD4+ T-cells
predominantly displayed the effector memory phenotype as
described for HCV and LCMV infection, indicating that CD4+
T-cells during chronic HBV have the capacity to transit through
an effector stage with faultless first line defence as acute-resolving
patients express comparable frequencies of Tem CD4+ T-cells.
[26,27]. Since we know that CD8+ T-cell exhaustion is associated
with sustained expression of multiple inhibitory molecules, we
defined the impact of a set of inhibitory receptors and were able to
demonstrate that exclusively PD-1 correlated to chronic HBV
infection. Surprisingly, CD4+ T-cells even displayed reduced
CTLA-4, TIM-3, KLRG1 and CD244 expression as compared to
CD8+ T-cells, suggesting less exhausted CD4+ T-cells [2–5,19]. In
the face of depressed expression of inhibitory molecules, we
consecutively asked for T-cell senescence as a possible patho-
mechanism next to T-cell exhaustion resulting in CD4+ T-cell
dysfunction. However, low frequencies of CD57 expression
Figure 3. Effect of PD-L1/2 blockade on CD4+ T-cell expansion. Induction of CD4+ T-cell proliferation in chronic HBV (n = 23) from h0 (left) to
antigenic stimulation (middle) and PD-L1/2 blockade (right) illustrated as point to point graphs from (A) PD-L1/2 responders (n = 9) and (B) Non-
responders (n = 14). Contour plots are shown for each group. (C) Patients treated with nucleosid/nucleotid analogs (black bars) responded to PD-1
blockade using Chi2-test, indicating that viral control let enhance patients susceptibility as (D) treated patients are characterized by low viremia. (E)
Decreased PD-1 expression in PD-L1/2 responders (R) (n = 6) versus non-responders (NR) (n = 6). (F) CD4+ T-cell frequencies upon antigenic
stimulation (black bars) and PD-L1/2 inhibition (grey bars) in relation to PD-1 expression.
doi:10.1371/journal.pone.0105703.g003
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propably implicate less significance of CD4+ T-cell senescence in
chronic HBV infection. PD-1 expression in chronic HBV infection
was not influenced by viral load as previously shown within other
viral entities [7,11,28]. Elevated PD-1 expression as described in
acute HBV infection might play a mechanistic role in the
prevention of overwhelming CD4+ T-cell immunity to avoid T-
cell-mediated acute liver failure. Importantly, PD-1 expression
seemed to be inversely correlated to CD127 as described for CD8+
T-cells [2,18]. Low PD-1 expression came along with high CD127
expression, indicating that high PD-1 expression led to a
diminished capability of CD4+ T-cells to maintain memory
potential, although similar profiles of T-cell differentiation are
shown for acute-resolving and chronic HBV. Indeed, higher PD-1
expression was associated with disrupted CD4+ T-cell expansion,
while CD4+ T-cells with PD-1 expression less than 90% regain
their proliferative capacity. Functional experiments testing the
effect of PD-L1/2 neutralization on CD4+ T-cell expansion
identified individualized patterns of responsiveness with enhanced
T-cells proliferation almost in treated patients with successful viral
control. These data are novel and provide important findings to
immunological approaches for prospective therapeutic interven-
tions in persisting HBV, but have limited validity due to low
numbers of patients investigated. Importantly, our data even
suggest that CTLA-4 and TIM-3 single blockade failed to
reactivate CD4+ T-cell function, which is limited by low numbers
of patients investigated but probably denoted a fundamental
insusceptibility of HBV-specific CD4+ T-cells as previously
described for CD8+ T-cells in chronic HCV infection [9]. In
contrast, Nebbia et al. was able to rescue HBV-specific CD8+ T-
cell responses by blocking TIM-3/galectin-9 interactions comple-
mentary to PD-1 pathway inhibition, suggesting distinct suppres-
sive effects of inhibitory molecules as TIM-3 on CD4+ and CD8+
T-cells [22]. Associations of reduced PD-1 expression with
improved PD-L1/2 responsiveness are consistent with previous
reports in HCV infection [6,11,29]. In contrast, PD-1highCD4+ T-
cells in HIV are more susceptible to PD-L1 blockade than PD-
1lowCD4+ T-cells, suggesting that functional influences of PD-1
might differ between viral entities [8]. In our experiments, PD-1
blockade partially improves the ability of CD4+ T-cells to produce
IFN-c, IL-2 and TNF-a. This entire reduced reactivation of
cytokine release was still described in HCV and emphasizes
limited ability of PD-L1/2 neutralization to revitalize CD4+ T-cell
effector functions [11]. Described heterogeneous patterns of CD4+
T-cell reactivation might be explained by (i) the complex
interaction of inhibitory molecules, (ii) the impact of different
transcriptional molecules as T-bet and EOMES [30,31], and (iii)
Figure 4. Effect of PD-L1/2 blockade on cytokine release. Analysis of cytokine+CD4+ T-cells allows to differ (A) PD-L1/2 responders (n = 4) from
(B) Non-responders (n = 9). Floating bars illustrate mean values ranging from minimun to maximum production of IFN-c, IL-2 and TNF-a seperatly
following antigen stimulation (white bars) and PD-1 blockade (grey bars). Contour plots are shown for IFN-c (top), IL-2 (middle) and TNF-a (bottom)
secretion upon antigen stimulation (left) and PD-1 pathway neutralization (right) after gating on CD3+CD4+ T-cells.
doi:10.1371/journal.pone.0105703.g004
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the altered expression of T-cell receptor-mediated downstream
signalling molecules. Further studies illuminating these questions
particularly regarding clinical parameters would be necessary to
provide additional insights into patterns of CD4+ T-cell revers-
ibility in HBV. In summary, we characterized for the first time the
disrupted CD4+ T-cell immunity during chronic HBV infection by
defining the inhibitory phenotype and the changes of CD4+ T-cell
function upon PD-1 inhibition using a novel MHC class II
Tetramer. These findings provide new insights into the mecha-
nisms underlying CD4+ T-cell dysfunction and revealed that
exhausted HBV-specific CD4+ T-cells were strongly linked to high
PD-1 expression with reactivation of CD4+ T-cell proliferation
which depends on treatment-associated viral control.
Supporting Information
Figure S1 Validation of MHC class II Tetramer. (A) HBV
core antigens 51–70, 61–80 and 111–130 yielded the strongest
response in acute HBV (n = 38) as 3 of 18 overlapping peptides
(20 mer) covering the core region using 3H-thymidine prolifera-
tion assay. (B) Epitope 61–80 was most frequently recognized by
DRB1*01-positive patients (n = 4) with acute HBV. (C) Staining of
clone cells specific for epitope 60–75 with unspecific HCV
Tetramer 1806–1818 (left) and specific HBV Tetramer 60–75
(right). (D) Clone cells were titrated into Tetramer negative
PBMC. The number of added clone cells was correlated to the
number of cells detected by specific Tetramer.
(TIF)
Figure S2 T-cell senescence and PD-1 expression in
correlation to viral load. (A) CD57 revealed low expression in
acute HBV (n = 6), EBV (n = 6), chronic HBV (n = 12) and Flu
(n = 9) infection, indicating less significance of T-cell senescence
during AHB and CHB. (B) Contour plots display virus-specific
CD57 expression after gating on CD142, CD192, Via Probe2
CD4+ T-cells. (C) Bar graphs from chronic untreated (black bars)
.2.000 IU/ml (n = 5), ,2.000 IU/ml (n = 12) and treated (white
bar) (n = 8) HBV patients are illustrating no differences in virus-
specific PD-1 expression in correlation to viral load.
(TIF)
Figure S3 Effect of PD-L1/2 blockade on Flu-specific as
well as CTLA-4 and TIM-3 blockade on HBV-specific
CD4+ T-cell expansion. (A) Induction of Flu-specific CD4+ T-
cell proliferation in chronically infected HBV patients (n = 8) from
h0 (left) to antigenic re-stimulation (middle) and PD-L1/2 blockade
(right) illustrated as point to point graphs. Contour plots are shown
for Tetramer+CD4+ T-cell proliferation upon antigen stimulation
(left) and PD-1 neutralization (right). (B) Induction of CD4+ T-cell
proliferation in chronically infected HBV patients following
CTLA-4 (left) (n = 7) and TIM-3 (right) (n = 4) blockade illustrated
as point to point graphs.
(TIF)
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